MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

All articles tagged: Diffuse large B-cell lymphoma, intra-abdominal lymph nodes (C83.33)

HealthDay 26 June at 06.03 PM

Glofitamab + GemOx Superior to Rituximab + GemOx for Lymphoma

Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at the annual hybrid congress of the European Hematology Association, held from June 13 to 16 in Madrid.Jeremy Abramson, M.D., from the Massachusett

Evalytics 19 March at 06.04 AM

FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLL

The FDA has granted accelerated approval for lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, in certain adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Developed by Juno Therapeutics, the therapy, branded as Breyanzi, targets CD19 and is approved for patients who've undergone at least two prior lines of therapy, including specif

HealthDay 04 January at 03.44 PM

Liso-Cel Cost-Effective for Second-Line Relapsed/Refractory Lymphoma

Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published online Dec. 28 in Blood Advances.Jee H. Choe, from the University of Southern California in Los Angeles, and colleagues evaluated the cost